April 10, 2018 07:05 AM EDT
R&D

Af­ter yet an­oth­er PhI­II Alzheimer's fail­ure, ex­perts try to map a path out of the wreck­ing field

John Carroll

Editor & Founder

Pushed by a 15-year record of clin­i­cal fail­ures and pulled by an FDA search­ing for a prac­ti­cal new path for­ward for Alzheimer’s drug re­search, a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Executive Director, Marketing

Celldex Therapeutics

Hampton, NJ, USA

TRENDING NOW

Bio­haven stock sinks on three-month de­lay for neu­ro drug's FDA ap­proval de­ci­sion

Mer­ck KGaA will con­tin­ue to add a tar­iff sur­charge for US cus­tomers 

Hen­grui, one of Chi­na's lead­ing biotechs, an­tic­i­pates $1.2B in pro­posed Hong Kong list­ing

FDA gives Ab­b­Vie ac­cel­er­at­ed ap­proval for an­ti­body-drug con­ju­gate in lung can­cer

Sanofi touts $20B in­vest­ment in US over five years

GSK to pay $1.2B up­front to snag Boston Phar­ma’s mid-stage MASH hope

A service from the Financial Times